R&D | February 24, 2026
Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Subscribe To Our Newsletter & Stay Updated
